Vaccine Success Undercut By Low Power Trial Results
investigativeeconomics.substack.com
Two potential vaccines for the COVID-19 virus have been announced from Pfizer/BioNTech and Moderna pharmaceuticals with success rates of 95% and 90% respectively. For the Pfizer/BioNTech messenger RNA (mRNA) drug, BNT162b2, it was tested in an equal split, double-blinded trial, and 169 placebo recipients would test positive for COVID-19, whereas only 9 vaccine recipients did.
Vaccine Success Undercut By Low Power Trial Results
Vaccine Success Undercut By Low Power Trial…
Vaccine Success Undercut By Low Power Trial Results
Two potential vaccines for the COVID-19 virus have been announced from Pfizer/BioNTech and Moderna pharmaceuticals with success rates of 95% and 90% respectively. For the Pfizer/BioNTech messenger RNA (mRNA) drug, BNT162b2, it was tested in an equal split, double-blinded trial, and 169 placebo recipients would test positive for COVID-19, whereas only 9 vaccine recipients did.